Abstract:ObjectiveTo investigate the incidence of natural resistance mutations to direct-acting antiviral agents (DAAs) in patients with chronic hepatitis C (CHC) in Beijing, China, and to compare the natural resistance mutations to DAAs in interferon (IFN)/ribavirin (RBV) treatment-experienced and treatment-nave patients. MethodsA total of 101 CHC patients with genotype 1b who visited Peking University First Hospital from July 2009 to November 2013 were enrolled, among whom 40 patients were once treated with IFN/RBV and 61 patients were not treated with IFN/RBV. The patients′ HCV RNA was extracted, and polymerase chain reaction was applied for amplification. The genes in HCV NS3, NS5A, and NS5B regions were sequenced, sequence alignment and resistance analysis were performed, and the incidence of natural resistance was compared. The t-test was applied for comparison of normally distributed continuous data between groups, and the Mann-Whitney U rank sum test was applied for comparison of abnormally distributed continuous data between groups. The chi-square test or Fisher's exact test was applied for comparison of categorical data between groups. ResultsThe sequences of NS3, NS5A, and NS5B regions were obtained from 84 (83.17%), 92 (91.09%), and 97 (96.04%) patients, respectively. The natural resistance mutations to DAAs in NS3 region occurred in 7 patients (8.33%) (T54S, n=1, 1.19%; R117H, n=5, 5.95%; N174F, n=1, 1.19%), those in NS5A region occurred in 19 patients (20.65%) (L28M, n=7, 7.61%; L31M, n=1, 1.09%; P58S, n= 4, 4.35%; Y93H, n=7, 7.61%), and those in NS5B region occurred in 95 patients (97.94%) (L159F, n=1, 1.03%; C316N, n=92, 94.85%; A421V, n=6, 6.18%; R422K, n=1, 1.03%; M426L, n=3, 3.09%; V499A, n=38, 39.18%). The incidence of resistance mutations to DAAs in NS3, NS5A, and NS5B regions showed no significant difference between the IFN/RBV treatment-experienced and treatment-nave patients (all P＞0.05). ConclusionNatural resistance mutations to DAAs exist in the treatment-nave CHC patients with genotype 1b in Beijing. Most of these mutations are low resistance mutations, and their effects on the clinical efficacy of DAAs need further investigation. The association between IFN/RBV treatment and increased natural resistance mutations to DAAs was not observed in CHC patients.

Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus.

Clinical efficacy and safety of ravidavir-based antiretroviral regimen in treatment of patients with chronic hepatitis C

Mechanism of resistance to direct-acting antivirals in hepatitis C treatment and management

Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients

Analysis of drug-resistance-associated mutations and genetic barriers in hepatitis C virus NS5B sequences in China

Resistant-Associated Substitutions Do Not Affect HCV RNA and HCV Core Antigen Clearance During Direct-Acting Antiviral Agent Treatment in a Real-World Setting

Natural resistance mutations to direct-acting antiviral agents in interferon/ribavirin treatment-experienced and treatment-naive patients with chronic hepatitis C in Beijing, China

Prevalence of HCV resistance-associated substitutions among treatment-failure patients receiving direct-acting antiviral agents

Prevalence of HCV Resistance-Associated Substitutions amongTreatment FailurePatients receiving Direct-Acting Antiviral Agents.

Changes of Inflammatory Cytokines/chemokines During Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin Therapy for Patients with Genotype 1b Hepatitis C Infection

Research of HCV variants resistant to direct-acting antiviral agents

Efficacy and Safety of Combined Directly Acting Antivirals for Treatment of Chinese Chronic Hepatitis C Patients in a Real-World Setting

An Increase in the Prevalence of Clinically Relevant Resistance-Associated Substitutions in Four Direct-Acting Antiviral Regimens: A Study Using GenBank HCV Sequences

Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients

Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China

World-wide Prevalence of Substitutions in HCV Genome Associated With Resistance to Direct-Acting Antiviral Agents

Influencing factors for direct-acting antiviral therapy failure in treatment of hepatitis C

Analysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors

Molecular characterization of the nonstructural 5A (NS5A) region of hepatitis C virus in Thai blood donors

Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis

Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients.